Contraceptive choices for females with congenital heart disease

Progress in Pediatric Cardiology

Volumn 19, Issue 1, 2004, Pages 15-24

  Miner, Pamela D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Congenital heart disease; Contraception; Counseling

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ASCORBIC ACID; CONTRACEPTIVE AGENT; COPPER INTRAUTERINE DEVICE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETONOGESTREL; GESTAGEN; GRISEOFULVIN; HYPERICUM PERFORATUM EXTRACT; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NESTERONE; NOMEGESTROL ACETATE; NORETHISTERONE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; ORTHOEVRA; PENICILLIN G; RIFAMPICIN; SPERMICIDAL AGENT; TETRACYCLINE; UNCLASSIFIED DRUG; VALPROIC ACID;

AMENORRHEA; BREAKTHROUGH BLEEDING; BREAST CANCER; BREAST TENDERNESS; CONDOM; CONGENITAL HEART DISEASE; COUNSELING; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE CONTRACEPTIVE DEVICE; FLUID RETENTION; HEADACHE; HEART INFARCTION; HORMONAL CONTRACEPTION; HUMAN; HYPERTENSION; INSTRUMENT STERILIZATION; INTRAUTERINE CONTRACEPTIVE DEVICE; LEUKORRHEA; LIBIDO DISORDER; LIVER TUMOR; MENSTRUAL IRREGULARITY; NAUSEA AND VOMITING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SPOTTING; THERAPEUTIC ABORTION; TRANSDERMAL PATCH; UNPLEASANT SENSATION; UTERINE TUBE LIGATION; VAGINA RING; VAGINITIS; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

EID: 2342628542     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2003.01.021     Document Type: Article

References (43)

1. Mendelson M.A. Contraception for women with congenital heart disease. Heart Dis Stroke. 3:1994;266-269
2. Seifert-Klauss V., Kaemmerer H., Brunner B., Schneider K.T., Hess J. Contraception in patients with congenital heart defects. Z Kardiol. 89:(7):2000;606-611
3. Sciscione A.C., Callan N.A. Pregnancy and contraception. In congenital heart disease in adolescents and adults. Cardiol Clin. 11:(4):1993;701-709
4. Fraser I.S. Forty years of combined oral contraception: the evolution of a revolution. MJA. 173:(20):Nov 2000;541-544
5. Shulman L.P. Update in contraception: oral contraceptives, risks. Obstet Gynecol Clin. 27:(4):2000;695-704
6. Burkman R.T., Collins J.A., Schulman L.P., Williams J.K. Current perspectives on oral contraceptive use. Am J Obstet Gynecol. 185:2001;S4-S12
7. Benagiano G., Primiero F.M. Safety of modern oral contraception: the options for women: lessons to be learned. Hum Reprod Update. 5:(6):1999;633-638
8. Hatcher R.A., Trussell J., Stewart F., Kowal D., Guest F., Cates W. Jr, et al. Contraceptive Technology. 17th ed :1998;Ardent Media, New York
9. Likis F.E. Contraceptive applications of estrogen. J Midwifery Women Health. 47:(3):2002;139-156
10. Roumen F.J.M.E., Apter D., Mulders T.M.T., Dieben T.O.M. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 16:2001;469-475
11. Smallwood G.H., Meador M.L., Lenihan J.P., Shangold G.A., Fisher A.C., Creasy G.W., et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol. 98:2001;799-805
12. Cosmi B., Legnani C., Bernardi F., Coccheri S., Palareti G. Value of family history in identifying women at risk of venous thromboembolism during oral contraception: observational study. BMJ. 322:2001;1024-1025
13. Burkman R.T. Oral contraceptives: current status. Clin Obstet Gynecol. 44:(1):2001;62-72
14. Farley T.M., Collins J., Schlesselman J.J. Hormonal contraception and risk of cardiovascular disease; an international perspective. Contraception. 57:1998;211-230
15. Kjerulff K.H., Erickson B.A., Langenberg P.W. Chronic gynecological conditions reported by US women: findings from the National Health Interview Survey, 1984-1992. Am J Public Health. 86:1996;195-199
16. Kaunitz A.M. Injectable contraception: new and existing options. Obstet Gynecol Clin N Am. 27:2000;741-780
17. Parsey K.S., Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 61:2000;105-111
18. Glasier A. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception. 65:(1):2002;29-37
19. Siven I., Camodonico I., Kirwat P., Holma P., Diaz S., Wan L., et al. The performance of levonorgestrelrod and Norplant contraceptive implants: a 5-year randomized study. Hum Reprod. 13:1998;3371-3378
20. Weaver K., Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review. Contraception. 59:(2):1999;71-78
21. Dickinson B.D., Altman R.D., Nielsen N.H., Sterling M.L. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol. 98:(5):2001;853-860
22. Biffignand P.M., Bilia A.R. The growing knowledge of St. John's Wort drug interactions and their clinical significance. Curr Ther Res. 61:(7):July 2000;389-394
23. Sarkar N.N. Mifespristone: bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol. 101:(2):2002;113-120
24. Vasilakis C., Jick S.S., Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception. 59:1999;79-83
25. Liying Z., Bilian X. Emergency contraception with Multiload Cu-375 SL IUD: a multicenter clinical trial. Contraception. 64:(2):2001;107-112
26. WHO task force on post-ovulatory methods of fertility regulations. Comparison of two doses of mifespristone in combination with misoprostol for early medical abortions: a randomized trial. Br J Obstet Gynecol 2000; 107:524-530
27. Stanwood N.L., Garrett J.M., Konrad T.R. Obstetrician-gynecologists and the intrauterine device: a survey of attitudes and practice. Obstet Gynecol. 99:(2):2002;275-280
28. Shelton J.D. Risk of clinical pelvic inflammatory disease attributable to an intrauterine device. Lancet. 357:(9254):2001;443
29. Ortiz M.E., Croxatto H.B., Bardin C.W. Mechanisms of action of intrauterine devices. Obstet Gynecol Surv. 51:(12 suppl):1996;S42-S51
30. Canavan T.P. Appropriate use of the intrauterine device. Am Fam Physician. 58:(9):1998;2077-2089
31. American College of Obstetricians and Gynecologists. The intrauterine device 1992. ACOG technical bulletin no. 164. Washington DC ACOG
32. Escobedo L.G., Peterson H.B., Grubb G.S., Franks A.L. Case-fatality rates for tubal sterilization in US hospitals, 1979-1980. Am J Obstet Gynecol. 160:1989;147-150
33. Peterson H.B., DeStefano F., Rubin G.L., Greenspan J.R., Lee N.C., Ory H.W. Deaths attributable to tubal sterilization in the United States, 1977-1981. Am J Obstet Gynecol. 146:1983;131-136
34. Diliento L., Somerville J., Presbitero P., Menti L., Brach-Prever S., Rizzoli G., et al. Eisenmenger syndrome: factors relating to deterioration and death. Eur Heart J. 19:1998;1845-1855
35. Ammash N.M., Connolly H.M., Abel M.D., Warnes C. Non-cardiac surgery in Eisenmenger syndrome. J Am Coll Cardiol. 33:(1):Jan 1999;222-227
36. Westhoff C., Davis A. Tubal sterilization: focus on the US experience. Fertil Steril. 73:(5):May 2000;913-922
37. Carre-Brendal V.E., Stewart D.R., Harrington D.C., Dhaka V.K., Breining M.S., Vancaillie T. A new transcervical sterilization procedure - 6 month pre-clinical results. Obstet Gynecol. 97:(Suppl 4):April 2001;S15-S16
38. McCarty M.F. Concurrent administration of sustained-release bezafibrate may counteract the increased thrombotic risk associated with oral estrogen therapy. Med Hypotheses. 57:(2):2001;216-220
39. Somerville J. The woman with congenital heart disease. Eur Heart J. 19:1998;1766-1775
40. Leonard H., O'Sullivan J.J., Hunter S. Family planning requirements in the adult congenital heart disease clinic. Heart. 76:1996;60-62
41. Pitsavos C., Stefanadis C., Toutouzas P. Contraception in women at high risk or with established cardiovascular disease. Ann NY Acad Sci. 900:2000;215-227
42. World Health Organization. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception. 57:(5):1998;315-324
43. Canobbio M.M. Health care issues facing adolescents with congenital heart disease. J Pediatr Nurs. 16:(5):2001;363-370